+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immune Checkpoint Inhibitors Market - Global Forecast 2026-2032- Product Image
Immune Checkpoint Inhibitors Market - Global Forecast 2026-2032- Product Image
New

Immune Checkpoint Inhibitors Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 197 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5888905
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The immune checkpoint inhibitors market stands at a pivotal moment as scientific innovation, regulatory change, and the emphasis on value-based care shape new standards for oncology. Senior leaders can leverage current market momentum to align strategic investments across R&D, commercialization, and supply chain operations for sustained competitive advantage.

Market Snapshot: Immune Checkpoint Inhibitors Market Growth and Outlook

The Immune Checkpoint Inhibitors Market is projected to increase from USD 48.64 billion in 2025 to USD 52.06 billion in 2026, reaching USD 84.45 billion by 2032 with a CAGR of 8.19%. This robust growth reflects rising demand across major oncology indications, broader adoption of combination therapies, and the integration of biomarker-driven approaches. The market outlook remains strong, supported by updates in clinical guidelines, interest from payers in treatments with durable benefit, and ongoing global expansion efforts. Market participants need to be ready for evolving stakeholder priorities and diversify their portfolios to meet emerging clinical unmet needs.

Scope & Segmentation

This report delivers extensive coverage of the immune checkpoint inhibitors landscape, enabling a detailed understanding of performance across geographies, care settings, and clinical applications.

  • Indications: Bladder cancer, head and neck cancer, melanoma, non-small cell lung cancer, and renal cell carcinoma are key therapeutic areas, driven by increased adoption and evidence supporting use in both initial and advanced disease.
  • Lines of Therapy: Evaluation of both first-line and second-line populations highlights the impact of prior therapies on regimen selection and the growing importance of personalized combinations.
  • Mechanisms of Action: CTLA-4, PD-1, and PD-L1 inhibitors represent the mechanistic diversity in this space, with agents such as ipilimumab, cemiplimab, nivolumab, pembrolizumab, atezolizumab, avelumab, and durvalumab contributing to a differentiated portfolio.
  • Care Settings: Analysis includes ambulatory surgical centers, cancer research institutes, hospitals, and specialty clinics, each influenced by operational, reimbursement, and patient access considerations.
  • Administration Routes: Intravenous administration remains standard, with a notable industry shift toward subcutaneous options aimed at improving patient convenience and reducing costs.
  • Geographic Regions: The report investigates the Americas, EMEA, and Asia-Pacific, placing emphasis on differences in regulatory timelines, payer landscapes, market uptake, and infrastructure to inform entry and expansion strategies.

Key Takeaways from the Immune Checkpoint Inhibitors Market Report

  • Integrated evidence generation, including both randomized clinical trials and real-world data, now forms the foundation for benefit-risk assessments and market access planning for all stakeholders.
  • The shift from single-agent therapies to tailored combination regimens is accelerating, with biomarker-guided patient selection supporting improved therapeutic outcomes and precision oncology initiatives.
  • Advances in subcutaneous formulation technologies are enabling delivery in alternative care settings, supporting operational efficiency and addressing provider and patient satisfaction goals.
  • Companies are placing renewed focus on diagnostic partnerships and strengthening manufacturing resilience to reduce geopolitical risk and maintain reliable global supply.
  • Responding to regional disparities in regulation and reimbursement now requires market-specific commercial strategies and local stakeholder engagement to drive sustainable patient access.

Tariff Impact on Immune Checkpoint Inhibitors Supply Chains

Recent U.S. tariff measures have created new complexities within biologics supply chains, impacting monoclonal antibody manufacturing and associated devices. Higher input costs are prompting manufacturers to reassess supplier networks, invest in regional production, and refine inventory strategies. These trends are reshaping costs at treatment centers and within integrated networks. Industry responses include contractual risk mitigation, pursuit of local manufacturing incentives, and targeted efforts to harden supply chain resilience for uninterrupted patient therapy and secure future R&D budgets.

Methodology & Data Sources

Our analysis combines primary interviews with clinical, payer, and operational experts, systematic reviews of peer-reviewed literature and regulatory reports, and meta-analysis of pivotal trial data. Trade data and regulatory frameworks inform supply chain and policy impact assessments. Expert triangulation ensures the reliability and relevance of findings.

Why This Report Matters

  • Informs strategic planning by mapping how emerging clinical, market, and regulatory trends will shape product innovation, launch timing, and patient access paths.
  • Supports R&D, commercial, and operational teams with practical, data-driven insights to harmonize investment priorities with evolving market requirements.
  • Equips top decision-makers to proactively manage clinical, policy, and supply dynamics across global markets to secure sustained growth.

Conclusion

Immune checkpoint inhibitors are reshaping oncology with new therapeutic combinations and broader patient reach. Cross-functional alignment and robust supply chains will remain critical as companies aim to deliver continued value for patients and stakeholders.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Immune Checkpoint Inhibitors Market, by Indication
8.1. Bladder Cancer
8.2. Head And Neck Cancer
8.3. Melanoma
8.3.1. First Line
8.3.2. Second Line
8.4. Non Small Cell Lung Cancer
8.4.1. First Line
8.4.1.1. Combination Therapy
8.4.1.2. Monotherapy
8.4.2. Second Line
8.4.2.1. Combination Therapy
8.4.2.2. Monotherapy
8.5. Renal Cell Carcinoma
9. Immune Checkpoint Inhibitors Market, by Mechanism Of Action
9.1. CTLA-4 Inhibitors
9.2. PD-1 Inhibitors
9.2.1. Cemiplimab
9.2.2. Nivolumab
9.2.3. Pembrolizumab
9.3. PD-L1 Inhibitors
9.3.1. Atezolizumab
9.3.2. Avelumab
9.3.3. Durvalumab
10. Immune Checkpoint Inhibitors Market, by Route Of Administration
10.1. Intravenous
10.2. Subcutaneous
11. Immune Checkpoint Inhibitors Market, by End User
11.1. Ambulatory Surgical Centers
11.2. Cancer Research Institutes
11.3. Hospitals
11.4. Specialty Clinics
12. Immune Checkpoint Inhibitors Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Immune Checkpoint Inhibitors Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Immune Checkpoint Inhibitors Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Immune Checkpoint Inhibitors Market
16. China Immune Checkpoint Inhibitors Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Agenus Inc.
17.6. Akeso, Inc.
17.7. Amgen Inc.
17.8. Astellas Pharma Inc.
17.9. AstraZeneca PLC
17.10. BeiGene Ltd.
17.11. Bristol-Myers Squibb Company
17.12. Celldex Therapeutics, Inc.
17.13. Coherus BioSciences, Inc.
17.14. Eli Lilly and Company
17.15. Immutep Ltd.
17.16. Incyte Corporation
17.17. Innovent Biologics, Inc.
17.18. Jiangsu Hengrui Medicine Co., Ltd.
17.19. Johnson & Johnson
17.20. Merck & Co., Inc.
17.21. Merck KGaA
17.22. NewLink Genetics Corporation
17.23. Novartis AG
17.24. Pfizer Inc.
17.25. Regeneron Pharmaceuticals, Inc.
17.26. Roche Holding AG
17.27. Sanofi S.A.
17.28. Shanghai Junshi Biosciences Co., Ltd.
17.29. Takeda Pharmaceutical Company Limited
List of Figures
FIGURE 1. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY AVELUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY AVELUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY AVELUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DURVALUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY DURVALUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 98. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 99. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 141. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 143. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 144. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 145. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 146. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 147. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 148. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 149. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 150. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 151. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 154. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 160. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 162. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 163. AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 164. AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 165. AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 166. AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 167. AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 168. AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 169. AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 170. AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 171. AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 172. AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 173. AFRICA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 186. ASEAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. ASEAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 188. ASEAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 189. ASEAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 190. ASEAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 191. ASEAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 192. ASEAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 193. ASEAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 194. ASEAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 195. ASEAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 196. ASEAN IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 197. GCC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 198. GCC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 199. GCC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 200. GCC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 201. GCC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 202. GCC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 203. GCC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 204. GCC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 205. GCC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 206. GCC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 207. GCC IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 208. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 209. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 210. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 211. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 213. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 219. BRICS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 220. BRICS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 221. BRICS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 222. BRICS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 223. BRICS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 224. BRICS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 225. BRICS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 226. BRICS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 227. BRICS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 228. BRICS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 229. BRICS IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 230. G7 IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 231. G7 IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 232. G7 IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 233. G7 IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 234. G7 IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 235. G7 IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 236. G7 IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 237. G7 IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 238. G7 IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 239. G7 IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 240. G7 IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 241. NATO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 242. NATO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 243. NATO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 244. NATO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 245. NATO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 246. NATO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 247. NATO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 248. NATO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 249. NATO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 250. NATO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 251. NATO IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 252. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 253. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 254. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 255. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 256. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 257. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 258. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 259. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 260. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 261. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 262. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 263. UNITED STATES IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 264. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 265. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 266. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 267. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 268. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
TABLE 269. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
TABLE 270. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 271. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 272. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 273. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 274. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Immune Checkpoint Inhibitors market report include:
  • Agenus Inc.
  • Akeso, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • BeiGene Ltd.
  • Bristol-Myers Squibb Company
  • Celldex Therapeutics, Inc.
  • Coherus BioSciences, Inc.
  • Eli Lilly and Company
  • Immutep Ltd.
  • Incyte Corporation
  • Innovent Biologics, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Merck KGaA
  • NewLink Genetics Corporation
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Shanghai Junshi Biosciences Co., Ltd.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages197
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 52.06 Billion
Forecasted Market Value ( USD ) by 2032 $ 84.45 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Immune Checkpoint Inhibitors for Cancer Market - Global Forecast 2026-2032 - Product Image

Immune Checkpoint Inhibitors for Cancer Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Immune Checkpoint Inhibitors - Global Strategic Business Report - Product Image

Immune Checkpoint Inhibitors - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Pd-1 and Pdl1 Inhibitors/ Immune Checkpoint Inhibitors Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Pd-1 and Pdl1 Inhibitors/ Immune Checkpoint Inhibitors Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Report 2025 - Product Image

PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Report 2025

  • Report
  • 250 Pages
  • Global
From
PD-1/PD-L1 Checkpoint Inhibitors Market - Global Forecast 2026-2032 - Product Image

PD-1/PD-L1 Checkpoint Inhibitors Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From

About the Immune Checkpoint Inhibitor Market

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease. Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs. Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.